Cart
sales@molnova.com
PF-05221304
CAS No. 1370448-25-1
PF-05221304 ( NSC 170984, R 6238, STAT5 Inhibitor III )
Catalog No. M23101 CAS No. 1370448-25-1
PF-05221304 is an orally bioavailable, liver-targeted inhibitor of acetyl-CoA carboxylase (ACC), an enzyme that catalyzes the first committed step in de novo lipogenesis (DNL).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 264 | In Stock |
|
| 10MG | 397 | In Stock |
|
| 25MG | 690 | In Stock |
|
| 50MG | 896 | In Stock |
|
| 100MG | 1305 | In Stock |
|
| 200MG | 1755 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePF-05221304
-
NoteResearch use only, not for human use.
-
Brief DescriptionPF-05221304 is an orally bioavailable, liver-targeted inhibitor of acetyl-CoA carboxylase (ACC), an enzyme that catalyzes the first committed step in de novo lipogenesis (DNL).
-
DescriptionPF-05221304 is an orally bioavailable, liver-targeted inhibitor of acetyl-CoA carboxylase (ACC), an enzyme that catalyzes the first committed step in de novo lipogenesis (DNL).
-
SynonymsNSC 170984, R 6238, STAT5 Inhibitor III
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1370448-25-1
-
Formula Weight502.57
-
Molecular FormulaC28H30N4O5
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCC(C)N1C2=C(CC3(CCN(C(C4=CC(C5=CC=C(C(O)=O)C=C5)=NC(OC)=C4)=O)CC3)CC2=O)C=N1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Thalidomide-propargy...
Thalidomide-propargyl is the Thalidomide-based Cereblon ligand used in the recruitment of CRBN protein.
-
Thalidomide-O-amido-...
Thalidomide-O-amido-C6-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker. It can be used in the synthesis of PROTACs.
-
MPEP
MPEP is a selective mGlu5 receptor antagonist with IC50 of 36 nM, exhibits no appreciable activity at mGlu1b/2/3/4a/7b/8a/6 receptors.
